365NEWSX
365NEWSX
Subscribe

Welcome

Covaxin Phase 1 Trial Clears Lancet Review, Phase 3 Trial Ongoing

Covaxin Phase 1 Trial Clears Lancet Review, Phase 3 Trial Ongoing

Covaxin Phase 1 Trial Clears Lancet Review, Phase 3 Trial Ongoing
Jan 22, 2021 47 secs

Covaxin, India's first indigenous vaccine against COVID-19, showed enhanced immune response without any serious side effects in the Phase 1 trials, according to the results published in well-respected Lancet Infectious Disease journal on Friday.

Similar peer-reviewed studies for the Phase 2 are still awaited and Phase 3 trials are ongoing even as the government continues to give out the jabs to lakhs of front-line workers.

The vaccine, which uses an inactivated virus to trigger an immune response, had raised concerns among experts over its emergency approval earlier this month by India's drug regulator while the Phase 3 trials are still underway.

The vaccine, codenamed BBV152, was well tolerated in all dose groups with no vaccine-related serious adverse events, noted the authors of the Lancet study funded by Bharat Biotech.

The authors said that all adverse events were mild and moderate, and were more frequent after the first dose, adding that one adverse event was reported but was unrelated to the vaccine.

Summarized by 365NEWSX ROBOTS

RECENT NEWS

SUBSCRIBE

Get monthly updates and free resources.

CONNECT WITH US

© Copyright 2024 365NEWSX - All RIGHTS RESERVED